Clinical data
Legal status
Routes of
CAS Registry Number  YesY
ATC code None
PubChem CID:
Chemical data
Formula C119H154ClN21O40
Molecular mass 2554.07 g/mol

Ramoplanin (INN) is a glycolipodepsipeptide antibiotic drug derived from strain ATCC 33076 of Actinoplanes.[1]


It exerts its bacteriocidal effect by inhibiting cell wall biosynthesis, acting by inhibiting the transglycosylation step of peptidoglycan synthesis.[2]


Its development has been fast-tracked by the U.S. Food and Drug Administration as a treatment for multiple antibiotic-resistant Clostridium difficile infection of the gastrointestinal tract,[3] although it is unstable in the bloodstream, so can be taken only orally against such infections.[4][5][6]


  1. ^ Farver DK, Hedge DD, Lee SC. Ramoplanin: a lipoglycodepsipeptide antibiotic. Annals of Pharmacotherapy. 2005 May;39(5):863-8. PMID 15784805
  2. ^ Fang X, Tiyanont K, Zhang Y, Wanner J, Boger D, Walker S. The mechanism of action of ramoplanin and enduracidin. Molecular Biosystems. 2006 Jan;2(1):69-76. PMID 16880924
  3. ^ Fulco P, Wenzel RP. Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent. Expert Review of Anti Infective Therapy. 2006 Dec;4(6):939-45. PMID 17181409
  4. ^ Scheinfeld N. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus. Journal of Drugs in Dermatology. 2007 Jan;6(1):97-103. PMID 17373167
  5. ^ Balagopal A, Sears CL. Clostridium difficile: new therapeutic options. Current Opinion in Pharmacology. 2007 Oct;7(5):455-8. PMID 17644040
  6. ^ Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clinical Infectious Diseases. 2008 Jan 15;46 Suppl 1:S32-42. PMID 18177219